Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ilofotase alfa - AM-Pharma Holding

Drug Profile

Ilofotase alfa - AM-Pharma Holding

Alternative Names: Human recombinant alkaline phosphatase; recAP; Recombinant optimised human alkaline phosphatase

Latest Information Update: 18 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AM-Pharma Holding
  • Developer AM-Pharma
  • Class Anti-inflammatories; Anti-ischaemics; Recombinant proteins
  • Mechanism of Action Endotoxin inhibitors; Enzyme replacements; Purinergic P1 receptor agonists; Purinergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypophosphatasia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Ulcerative colitis

Highest Development Phases

  • Phase III Acute kidney injury
  • Phase I/II Hypophosphatasia
  • No development reported Ulcerative colitis
  • Discontinued Septic shock

Most Recent Events

  • 16 Jan 2024 Phase-II clinical trials in Acute kidney injury (Prevention) (IV) (NCT06168799)
  • 13 Dec 2023 AM Pharma plans phase-II trial for Acute kidney injury (Prevention) in December 2023 (IV, infusion) (NCT06168799)
  • 11 Oct 2023 Adverse events, pharmacokinetics and pharmacodynamics data from a phase-I/II trial in Hypophosphatasia released by AM Pharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top